Erik Fredlund

List of Publications by Year
in descending order

33 papers	4,076 citations	257450 24 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	8731 citing authors

#	Article	IF	Citations
1	GLI1â€induced mammary gland tumours are transplantable and maintain major molecular features. International Journal of Cancer, 2020, 146, 1125-1138.	5.1	5
2	Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice. Nature Communications, 2020, 11, 394.	12.8	61
3	PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer. ELife, 2020, 9, .	6.0	15
4	Breast cancer quantitative proteome and proteogenomic landscape. Nature Communications, 2019, 10, 1600.	12.8	152
5	SubCellBarCode: Proteome-wide Mapping of Protein Localization and Relocalization. Molecular Cell, 2019, 73, 166-182.e7.	9.7	165
6	Mass Cytometry and Topological Data Analysis Reveal Immune Parameters Associated with Complications after Allogeneic Stem Cell Transplantation. Cell Reports, 2017, 20, 2238-2250.	6.4	59
7	Pericyteâ€“fibroblast transition promotes tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5618-27.	7.1	246
8	Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. Nature Communications, 2016, 7, 12321.	12.8	113
9	Frequency and distribution of Notch mutations in tumor cell lines. BMC Cancer, 2015, 15, 311.	2.6	15
10	PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription. Molecular Cell, 2015, 59, 984-997.	9.7	120
11	The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature, 2015, 517, 489-492.	27.8	285
12	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
13	<scp>CDK</scp>â€mediated activation of the <scp>SCF^{FBXO}</scp>²⁸ ubiquitin ligase promotes <scp>MYC</scp>â€driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Molecular Medicine, 2013, 5, 1067-1086.	6.9	61
14	Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes. Clinical Cancer Research, 2013, 19, 1353-1362.	7.0	23
15	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Research, 2012, 14, R113.	5.0	49
16	Neuroblastoma: Role of Hypoxia and Hypoxia Inducible Factors in Tumor Progression. Pediatric Cancer, 2012, , 137-149.	0.0	0
17	Hunting for Protein Markers of Hypoxia by Combining Plasma Membrane Enrichment with a New Approach to Membrane Protein Analysis. Journal of Proteome Research, 2011, 10, 1645-1656.	3.7	4
18	GOBO: Gene Expression-Based Outcome for Breast Cancer Online. PLoS ONE, 2011, 6, e17911.	2.5	361

#	Article	IF	Citations
19	The Notch and TGF-Î² Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma. PLoS ONE, 2011, 6, e23057.	2.5	56
20	The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Research, 2011, 39, e136-e136.	14.5	72
21	MYCN-regulated microRNAs repress estrogen receptor-Î± (ESR1) expression and neuronal differentiation in human neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1553-1558.	7.1	125
22	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-Î² Pathway in Neuroblastoma. Molecular Cell, 2010, 40, 762-773.	9.7	279
23	HIF-1Î± and HIF-2Î± Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1Î± Correlates Negatively to Advanced Clinical Stage and Tumor Vascularization. Clinical Cancer Research, 2009, 15, 7130-7136.	7.0	68
24	HIF-2Î± maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16805-16810.	7.1	131
25	Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer. Clinical Cancer Research, 2009, 15, 5552-5559.	7.0	22
26	HIF-1Î± induces MXI1 by alternate promoter usage in human neuroblastoma cells. Experimental Cell Research, 2009, 315, 1924-1936.	2.6	24
27	Transcriptional adaptation of neuroblastoma cells to hypoxia. Biochemical and Biophysical Research Communications, 2008, 366, 1054-1060.	2.1	23
28	High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14094-14099.	7.1	149
29	Hypoxia-Inducible Factor-2Î± Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer. Cancer Research, 2008, 68, 9212-9220.	0.9	130
30	Hypoxia Inducible Factor-2Î± in Cancer. Cell Cycle, 2007, 6, 919-926.	2.6	168
31	Recruitment of HIF-1Î± and HIF-2Î± to common target genes is differentially regulated in neuroblastoma: HIF-2Î± promotes an aggressive phenotype. Cancer Cell, 2006, 10, 413-423.	16.8	624
32	Hypoxia-induced dedifferentiation of tumor cells â€“ A mechanism behind heterogeneity and aggressiveness of solid tumors. Seminars in Cell and Developmental Biology, 2005, 16, 554-563.	5.0	262
33	Notch signaling in neuroblastoma. Seminars in Cancer Biology, 2004, 14, 365-373.	9.6	61